Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics has expanded the availability of its Precise MRD test to include breast, colorectal, and renal cancers, addressing a patient population of more than 6 million in the U.S. The expansion is supported by data from the prospective MONITOR-Breast study published in Future Oncology, which demonstrated 100% specificity in predicting pathological complete response and identified 44% more at-risk patients through longitudinal testing.
Key figures
- Specificity
- 100%
- Study patients
- 154
- Tracked variants
- 1000
- Baseline detection rate
- 93%
- Plasma samples analyzed
- 949
- Sustained clearance rate
- 78%
- Addressable market patients
- 6 million
- Ultrasensitive detection rate
- 20%
- Risk multiplier ctdna positive
- 47
- Persistent intermittent positivity
- 22%
- Additional at risk patients identified
- 44%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.